Diagnostic Comparison and Workflow Evaluation of Whole Body PET-magnetic Resonance and PET-CT With and Without Contrast Media in Patients With Oncologic Diseases

University of Zurich1 site in 1 country142 target enrollmentDecember 2014

ConditionsNeoplasm Staging

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Neoplasm Staging
Sponsor: University of Zurich
Enrollment: 142
Locations: 1
Primary Endpoint: Number of patients with correct TNM staging defined with PET/magnetic resonance versus PET/CT
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Diagnostic accuracy of PET/magnetic resonance and PET/CT will be compared concerning primary tumor, regional nodes, metastasis (TNM) staging and therapeutic influence. Workflow scenarios will be evaluated to create imaging protocols which are time efficient and diagnostically accurate.

Registry

clinicaltrials.gov

Start Date

December 2014

End Date

December 2016

Last Updated

9 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University of Zurich

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male and female patients from 18-90 years
•Written informed consent
•Patients with a proven or suspected oncological disease referred for a clinically -Indicated PET/CT with of without contrast media

Exclusion Criteria

•Pregnant or breast feeding women
•Non compliance of the patient to follow the study instructions (e.g. hearing problems, dementia)
•Inclusion in another clinical trial 30 days prior to inclusion
•Age \< 30years
•Contraindication for MRI (cardiac pacemaker, certain metal implants, claustrophobia
•Known allergies to contrast CT or MRI contrast media
•Patients with an glomerular filtration rate of \< 60ml/min/1.73m2